BridgeMD
New treatment option for Structural Heart Disease
Official title Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT
ClinicalTrials.gov ID: NCT06937983
What this study is testing
- What it's testing
- Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder. Special pacemakers called implantable cardiac defibrillators (ICDs) help treat VT episodes, however they do not prevent the VT episodes from occurring.
- Time commitment: about 12 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ≥18 years old
- Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable...
- Eligible for VT ablation as part of standard care (urgent or elective)
- Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional...
- Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system.
You likely can't join if
- Lacks capacity to provide informed consent
- New York Heart Association (NYHA) class IV heart failure
- Life expectancy of less than 12 months
- Implanted with a ventricular assist device
- Presence of mobile intracardiac thrombus
- Reversible cause of VT
See the full eligibility criteria
- ≥18 years old
- Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillator (ICD) devices)
- Eligible for VT ablation as part of standard care (urgent or elective)
- Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause with...
- Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system.
- Lacks capacity to provide informed consent
- New York Heart Association (NYHA) class IV heart failure
- Life expectancy of less than 12 months
- Implanted with a ventricular assist device
- Presence of mobile intracardiac thrombus
- Reversible cause of VT
- Women who are pregnant or nursing
- Both mechanical aortic and mitral valves
- Enrolment in a concurrent treatment clinical study that in the judgement of the investigator would increase risk to the patient or deem the patient inappropriate to participate in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Coventry, West Midlands, United Kingdom
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Coventry, West Midlands, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.